1. Alan Stein Alan Stein United States says:

    I don't want to seem picky or unreasonable, but I have to say that the MS community is, by and large, a well-informed group of people who keep up with the latest research and for whom scientific details really matter.

    So, when the rationale that is quoted for the continued development for Laquinimod is: "The results achieved in the previous Phase III trials of laquinimod support the clinical utility of this compound as a unique treatment option for multiple sclerosis", wouldn't it make sense for the article to describe what the Phase III results actually were??

    Just another couple of sentences would have provided the information necessary to understand how well Laquinimod stacks up against other potntial therapies under the FDA review process. But, without it, this article is just another burger that is mostly an oversize bun with very little beef underneath.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.